Regeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Analysts at Wolfe Research

Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note issued to investors on Friday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $1,150.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts have also commented on REGN. Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Barclays decreased their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. TD Cowen lifted their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. JPMorgan Chase & Co. cut their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Finally, Wells Fargo & Company dropped their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,099.55.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded down $25.70 during midday trading on Friday, reaching $756.81. 1,374,549 shares of the company were exchanged, compared to its average volume of 530,457. Regeneron Pharmaceuticals has a one year low of $753.69 and a one year high of $1,211.20. The stock has a market cap of $83.17 billion, a P/E ratio of 18.73, a PEG ratio of 3.04 and a beta of 0.15. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock’s 50-day moving average price is $985.21 and its 200-day moving average price is $1,032.97.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.48% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Quent Capital LLC boosted its stake in Regeneron Pharmaceuticals by 5.1% in the first quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 19 shares in the last quarter. Dorsey & Whitney Trust CO LLC lifted its stake in Regeneron Pharmaceuticals by 26.8% in the first quarter. Dorsey & Whitney Trust CO LLC now owns 587 shares of the biopharmaceutical company’s stock worth $565,000 after purchasing an additional 124 shares during the last quarter. Acadian Asset Management LLC boosted its position in Regeneron Pharmaceuticals by 37.2% during the first quarter. Acadian Asset Management LLC now owns 62,141 shares of the biopharmaceutical company’s stock valued at $59,794,000 after buying an additional 16,856 shares during the period. Cercano Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at about $36,953,000. Finally, Edgestream Partners L.P. purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $7,352,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.